Phase 2 study of HDAC inhibitor tucidinostat in combination with anti-PD-1 antibody in patients with locally advanced or metastatic urothelial carcinoma

被引：0
|
作者：
Liu, Zhuowei
Jiang, Lijuan
Li, Xiangdong
Ye, Yunlin
Wu, Zhiming
An, Xin
Shi, Yanxia
Yao, Kai
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Dept Urol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16563
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
    O'Neil, Bert H.
    Wallmark, John M.
    Lorente, David
    Elez, Elena
    Raimbourg, Judith
    Gomez-Roca, Carlos
    Ejadi, Samuel
    Piha-Paul, Sarina A.
    Stein, Mark N.
    Razak, Albiruni R. Abdul
    Dotti, Katia
    Santoro, Armando
    Cohen, Roger B.
    Gould, Marlena
    Saraf, Sanatan
    Stein, Karen
    Han, Sae-Won
    PLOS ONE, 2017, 12 (12):
  • [33] Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Bouattour, Mohamed
    Cheng, Ann-Lii
    Dayyani, Farshid
    Khalil, Danny
    Li, Daneng
    Liao, Chih-Yi
    Lopez, Carlos Lopez
    Rimassa, Lorenza
    Deutsch, Jonathan
    Pailden, Junvie
    Patel, Maulik
    Ng, Juki
    Henkel, Anne
    Ferlini, Cristiano
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03.
    Sheng, Xinan
    Chen, Haige
    Hu, Bin
    Yao, Xudong
    Liu, Ziling
    Yao, Xin
    Guo, Hongqian
    Hu, Yi
    Ji, Zhigang
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    Wu, Jin
    Zhou, Fangjian
    He, Zhisong
    Fan, Jinhai
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Phase 2 Study of NP-G2-044, a Novel Fascin Inhibitor, in Combination with Anti-PD-1 Therapy in Patients with Solid Tumors Resistant to Prior Anti-PD-1 Therapy
    Kasi, Anup
    Birrer, Michael
    Brown, Jason
    Chandrasekaran, Sanjay
    Chung, Vincent
    Frank, Richard
    Gadgeel, Shirish
    George, Thomas
    Jalal, Shadia
    Mendivil, Alberto
    Poklepovic, Andrew
    Segar, Jennifer
    Spira, Alexander
    Tanyi, Janos
    Zhang, Jillian
    Huang, Xin-Yun
    Jimeno, Jose
    Tsai, Frank V.
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [36] PHASE I STUDY OF INTRATUMORAL NBTXR3 IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH ADVANCED CANCERS
    Shen, Colette
    Frakes, Jessica
    Niu, Jiaxin
    Weiss, Jared
    Caudell, Jimmy
    Jameson, Katherine
    Said, Patricia
    Seiwert, Tanguy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A249 - A249
  • [37] MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
    Cui, C.
    Zhou, L.
    Yang, Y.
    Qu, W.
    Sheng, X.
    Chi, Z.
    Si, L.
    Mao, L.
    Lian, B.
    Wang, X.
    Yan, X.
    Li, S.
    Li, C.
    Wei, X.
    Li, J.
    Duan, R.
    Xu, H.
    Zhou, A.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1151 - S1151
  • [38] A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.
    Kim, Miso
    McDermott, Raymond S.
    Williamson, Stephen K.
    Cho, Byoung Chul
    Dowlati, Afshin
    Lakhani, Nehal J.
    Malhotra, Jyoti
    Kaczmar, John M.
    Papadopoulos, Kyriakos P.
    Safran, Howard
    Aljumaily, Raid
    Mani, Jayakumar
    Fang, Fang
    Chen, Shuquan
    Salvati, Mark
    Lowy, Israel
    Fury, Matthew G.
    Lewis, Karl
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 434 - 434
  • [39] Real-world retrospective study of anti-PD-1 antibody in combination with chemotherapy as a neoadjuvant treatment strategy for locally advanced resectable esophageal squamous cell carcinoma
    Liu, Can
    Yu, Yi
    Shao, Yuanyuan
    He, Lintao
    Wu, Tao
    Zheng, Jinxiu
    Chen, Jun
    Li, Junhe
    JOURNAL OF THORACIC DISEASE, 2024, 16 (07)
  • [40] Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
    Chen, Xiaozhong
    Wang, Wei
    Zou, Qingfeng
    Zhu, Xiaodong
    Lin, Qin
    Jiang, Yi
    Sun, Yan
    Shen, Liangfang
    Wang, Lin
    Zou, Guorong
    Lin, Xiaoyan
    Lin, Shaojun
    Li, Minying
    Wang, Ying
    Xu, Ruilian
    Ao, Rui
    Wang, Rensheng
    Lin, Haifeng
    Huang, Shuang
    Xu, Tingting
    Li, Wenting
    Xia, Mengying
    Xia, Yu
    Wang, Zhongmin
    Li, Baiyong
    Li, Jingao
    Hu, Chaosu
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
12345